Vitrolife interim report January - September 2003

2003-10-21 - 12:07

Vitrolife interim report January - September 2003 · Net sales for the group amounted to SEK 72.3 million (85.5) where 28.5 are assigned to business disposed 2002. Gross margin increased to 64% (52%), the group's operating result totalled SEK 38.8 million (-12.2). · Net sales for core activities increased by 27% to a total of SEK 72.3 million (57.0) and gross result increased by 56 % to SEK 46.3 million (29.5), the operating result amounted to SEK 3.7 million (-26.6). · The group's net result totalled SEK 39.6 million (-8.7). · Vitrolife sells subsidiaries A-life Ltd and A-life Inc for 60 MSEK plus royalty to Mentor Corp., USA. · Reduction of the share premium reserve of SEK 292 million settled. · Result per share amounted to SEK 2.16 (-0.47). Gothenburg, October 22, 2003. Vitrolife AB (Publ) For further information, please contact: Vitrolife CEO: Magnus Nilsson Tel: +46 31 721 80 00 Mobile +46 708 22 80 61 mnilsson@vitrolife.com CFO and IR agent: Margareta Fischer Tel: +46 31 721 80 00 Mobile: +46 708 22 80 13 mfischer@vitrolife.com Vitrolife is a global biomedical corporation that works with products for cell and tissue technology. The Vitrolife group consists of the parent company, Vitrolife AB (Publ) and two wholly owned subsidiaries: Vitrolife Sweden AB (Gothenburg, Sweden), Vitrolife Inc. (Denver, Colorado). The group's operations focused on three geographic areas. · Europe/Middle East · The Americas · Rest of the World Vitrolife's business concept is to develop, produce and sell advanced products and systems for the preparation, cultivation, preservation and support of cells, tissues and organs. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/10/21/20041110BIT21620/wkr0001.pdf The full report in Swedish